Scientists working on the new tuberculosis (TB) vaccine have taken a big step forward by showing that promising TB antigens and vaccine adjuvants are protected from heat damage with techniques developed at the University of Bath. can be protected.
Their method prevents decay of important components of the vaccine from outside the refrigerator.
This means that it is a thermally stable vaccine that can be reliably sent to remote areas throughout the world.
There is an urgent need not only for new tuberculosis vaccines, but also methods to keep non-cold chain vaccines stable, up to 50% of vaccine doses being discarded before use because they are not exposed to optimal temperatures. For this reason, the thermostable vaccine has been identified as a priority research area in the 2011-2020 World Health Organization Global Vaccination Action Plan.
Ensilication, a method developed at the University of Bath, shrinks vaccine proteins by using a layer of silicon dioxide that builds up around molecules in cells so they are not degraded when exposed to temperatures that normally rot. Proteins are held in place until they can be removed from cells and released with silica.
The research has shown for the first time that the ag85b TB antigen and vaccine that are integrated with the Sbi adjuvant protein can be degraded at temperatures above freezing.
They then showed that the vaccine’s components were protected from heat damage when treated and stored on a shelf for a long time at room temperature without losing structure and function.
This is the first time that the increase in protein thermal stability in a vaccine environment has been improved after working with the detection principle using protein models.
Further Reading: University of bath